# Evaluation of RC28-E Injection in Diabetic Retinopathy

> **NCT04782128** · PHASE2 · UNKNOWN · sponsor: **RemeGen Co., Ltd.** · enrollment: 120 (estimated)

## Conditions studied

- Diabetic Retinopathy

## Interventions

- **BIOLOGICAL:** RC28-E injection

## Key facts

- **NCT ID:** NCT04782128
- **Lead sponsor:** RemeGen Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-05-25
- **Primary completion:** 2024-05
- **Final completion:** 2024-07
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2023-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04782128

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04782128, "Evaluation of RC28-E Injection in Diabetic Retinopathy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04782128. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*